Publicacións nas que colabora con Jhonny Alberto Azuaje Guerrero (19)

2024

  1. Exploring Biginelli-based scaffolds as A2B adenosine receptor antagonists: Unveiling novel structure-activity relationship trends, lead compounds, and potent colorectal anticancer agents

    Biomedicine and Pharmacotherapy, Vol. 173

2023

  1. Exploring the Effect of Halogenation in a Series of Potent and Selective A2BAdenosine Receptor Antagonists

    Journal of Medicinal Chemistry, Vol. 66, Núm. 1, pp. 890-912

  2. Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugs

    Biomedicine and Pharmacotherapy, Vol. 164

2022

  1. A 2B adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models

    Journal for ImmunoTherapy of Cancer, Vol. 10, Núm. 5

  2. Exploring Non-orthosteric Interactions with a Series of Potent and Selective A3Antagonists

    ACS Medicinal Chemistry Letters, Vol. 13, Núm. 2, pp. 243-249

  3. Optimization of 2-Amino-4,6-diarylpyrimidine-5-carbonitriles as Potent and Selective A1Antagonists

    Journal of Medicinal Chemistry, Vol. 65, Núm. 3, pp. 2091-2106

2021

  1. 3,4-Dihydropyrimidin-2(1H)-ones as Antagonists of the Human A2B Adenosine Receptor: Optimization, Structure-Activity Relationship Studies, and Enantiospecific Recognition

    Journal of medicinal chemistry, Vol. 64, Núm. 1, pp. 458-480

2020

  1. Nitrogen-Walk Approach to Explore Bioisosteric Replacements in a Series of Potent A2B Adenosine Receptor Antagonists

    Journal of medicinal chemistry, Vol. 63, Núm. 14, pp. 7721-7739

2019

  1. Trifluorinated Pyrimidine-Based A2B Antagonists: Optimization and Evidence of Stereospecific Recognition

    Journal of Medicinal Chemistry, Vol. 62, Núm. 20, pp. 9315-9330

2018

  1. Clinical validation of blood/brain glutamate grabbing in acute ischemic stroke

    Annals of Neurology, Vol. 84, Núm. 2, pp. 260-273

2017

  1. Computer-aided design of multi-target ligands at A1R, A2AR and PDE10A, key proteins in neurodegenerative diseases

    Journal of Cheminformatics, Vol. 9, Núm. 1

  2. Development of Fluorescent Probes that Target Serotonin 5-HT2B Receptors

    Scientific Reports, Vol. 7, Núm. 1

  3. Effect of Nitrogen Atom Substitution in A3 Adenosine Receptor Binding: N-(4,6-Diarylpyridin-2-yl)acetamides as Potent and Selective Antagonists

    Journal of Medicinal Chemistry, Vol. 60, Núm. 17, pp. 7502-7511

  4. Enantiospecific Recognition at the A2B Adenosine Receptor by Alkyl 2-Cyanoimino-4-substituted-6-methyl-1,2,3,4-tetrahydropyrimidine-5-carboxylates

    Journal of Medicinal Chemistry, Vol. 60, Núm. 8, pp. 3372-3382

  5. Exploring the influence of the substituent at position 4 in a series of 3,4-dihydropyrimidin-2(1H)-one A2B adenosine receptor antagonists

    Chemistry of Heterocyclic Compounds, Vol. 53, Núm. 3, pp. 316-322

2016

  1. Drug structural features affect drug delivery from hyperbranched polyesteramide hot melt extrudates

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 102, pp. 1-8

2014

  1. Structure-based design of new KSP-Eg5 inhibitors assisted by a targeted multicomponent reaction

    ChemBioChem, Vol. 15, Núm. 10, pp. 1471-1480

2013

  1. Discovery of 3,4-dihydropyrimidin-2(1 H)-ones as a novel class of potent and selective A2B adenosine receptor antagonists

    ACS Medicinal Chemistry Letters, Vol. 4, Núm. 11, pp. 1031-1036

2012

  1. Discovery and preliminary SAR of 5-arylidene-2,2-dimethyl-1,3-dioxane-4,6- diones as platelet aggregation inhibitors

    Combinatorial Chemistry and High Throughput Screening, Vol. 15, Núm. 7, pp. 551-554